FibroGen Inc
(MEX:FGEN)
MXN
20.14
0.53 (2.7%)
Market Cap: 2.06 Bil
Enterprise Value: 1.56 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 46/100 - Q1 2024 FibroGen Inc Earnings Call TranscriptMay 06, 2024MXN20.25 (-6.98%)Earnings
- Q4 2023 FibroGen Inc Earnings Call TranscriptFeb 26, 2024MXN30 (-20.09%)Earnings
- FibroGen Inc KOL Investor Event Series Part I (Virtual) TranscriptFeb 13, 2024
- Q3 2023 FibroGen Inc Earnings Call TranscriptNov 06, 2023MXN15.08Earnings
- Q2 2023 FibroGen Inc Earnings Call TranscriptAug 07, 2023MXN31 (-90.91%)Earnings
- FibroGen Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- FibroGen Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 FibroGen Inc Earnings Call TranscriptMay 08, 2023MXN341.2Earnings
- Q4 2022 FibroGen Inc Earnings Call TranscriptFeb 27, 2023MXN461.5Earnings
- FibroGen Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Q3 2022 FibroGen Inc Earnings Call TranscriptNov 07, 2022MXN350.5Earnings
- Q2 2022 FibroGen Inc Earnings Call TranscriptAug 08, 2022MXN251Earnings
- Q1 2022 FibroGen Inc Earnings Call TranscriptMay 09, 2022MXN257.5Earnings
- Q4 2021 FibroGen Inc Earnings Call TranscriptFeb 28, 2022MXN314Earnings
- Q3 2021 FibroGen Inc Earnings Call TranscriptNov 09, 2021MXN246 (-8.21%)Earnings
- Q2 2021 FibroGen Inc Earnings Call TranscriptAug 09, 2021MXN278 (+0.36%)Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 04, 2021
- FibroGen Inc Annual Shareholders Meeting TranscriptMay 26, 2021
- FibroGen Inc at Bank of America Global Research Healthcare Conference (Virtual) - Fireside Chat TranscriptMay 13, 2021
- Q1 2021 FibroGen Inc Earnings Call TranscriptMay 10, 2021MXN386.14 (-6.25%)Earnings
- FibroGen Inc Provides Additional Information on Roxadustat - Conference Call TranscriptApr 06, 2021
- FibroGen Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 02, 2021
- Q4 2020 FibroGen Inc Earnings Call TranscriptMar 01, 2021MXN1037Earnings
- FibroGen Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- FibroGen Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
- Q3 2020 FibroGen Inc Earnings Call TranscriptNov 05, 2020MXN1012Earnings
- FibroGen Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- FibroGen Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2020
- Q2 2020 FibroGen Inc Earnings Call TranscriptAug 06, 2020MXN987Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2020
- FibroGen Inc Annual Shareholders Meeting TranscriptJun 04, 2020
- FibroGen Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2020
- FibroGen Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 FibroGen Inc Earnings Call TranscriptMay 07, 2020MXN900Earnings
- Q4 2019 FibroGen Inc Earnings Call TranscriptMar 02, 2020MXN800 (-2.91%)Earnings
- FibroGen Inc at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Q3 2019 FibroGen Inc Earnings Call TranscriptNov 11, 2019MXN645Earnings
- Q2 2019 FibroGen Inc Earnings Call TranscriptAug 08, 2019MXN740Earnings
- FibroGen Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 12, 2019
- Q1 2019 FibroGen Inc Earnings Call TranscriptMay 09, 2019MXN890Earnings
- Q4 2018 FibroGen Inc Earnings Call TranscriptFeb 27, 2019MXN865Earnings
FibroGen Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2020 / 08:15PM GMT
Release Date Price:
MXN908
(+0.89%)
Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst
Hi, everyone. Thanks for joining the session with FibroGen. I'm pleased to have with us the CEO, Enrique Conterno. Enrique, thanks for joining us today.
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
No, thank you very much, Joe. I very much appreciate the invitation. Look forward to discussing a number of topics.
Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst
Yes. Great. So I guess, I think a lot of viewers are going to be familiar with FibroGen, but some may not. So could you begin with an overview of what the key areas of focus are for FibroGen?
Enrique A. Conterno
FibroGen, Inc. - CEO & Director
Sure. So FibroGen is a company very much based in science. We've been able to progress 2 key products, one of them, roxadustat. The second one, pamrevlumab, which are very much in late stages. Roxa has already been commercialized in China and Japan and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)